Get the right experience for you. Please select your location and investor type.

Global Emerging Markets Leaders
The strategy invests in 25-60 high-quality emerging markets companies that we consider to be well positioned to contribute to, and benefit from, sustainable development.
The strategy was launched in April 2020. It invests in the shares of between 25-60 companies in emerging markets.
A Leaders strategy generally invests in market leading companies which means, for this strategy, that they are valued at over US$1 billion.
You can see all of the companies that this strategy invests in by filtering on our Portfolio Explorer tool.
- We define investment risk as losing clients’ money – this means we focus on looking after your money as well as growing it
- Companies must contribute to sustainable development and make a positive impact towards a more sustainable future. Portfolio Explorer >
- We invest in high-quality companies with exceptional cultures, strong franchises and resilient financials. How we pick companies >
- We avoid companies linked to harmful activities and engage and vote for positive change. Our position on harmful products >
Quarterly updates
Strategy update: Q1 2025
Global Emerging Markets Leaders strategy update: 1 January - 31 March 2025
With the threat of US tariffs ever present, many of the challenges emerging markets faced in the final quarter of 2024 carried over into 2025. Share prices in India fell sharply due to concerns about a slowdown in the economy. China, by contrast, performed well as investors anticipated faster economic growth and began to identify value in many parts of the market. This sentiment was also supported by President Xi, who met executives from a number of private-sector companies.
We added 10 new holdings over the quarter and sold seven. In China, we sold Glodon (China: Information Technology), Hangzhou Robam (China: Consumer Discretionary), WuXi Biologics (China: Health Care), Ping An Insurance (China: Financials) and Hong Kong Exchanges and Clearing (Hong Kong: Financials). We sold the first two companies because we believe the country's property market continues to have an issue with oversupply. Glodon provides software to construction and development companies and the majority of Hangzhou Robam’s appliances are sold to housing developers. WuXi Biologics was a small position and we couldn’t see any immediate prospect that the ongoing challenges posed by US government trade policy would be resolved. Although Ping An Insurance and Hong Kong Exchanges and Clearing had both performed well, we sold them to fund new investment ideas such as Alibaba (China: Consumer Discretionary), S.F. Holding (China: Industrials) and Mindray (China: Health Care).
Alibaba is one of China’s leading e-commerce platforms. S.F. Holding has grown into one of China’s leading logistics businesses since its foundation in 1992. Mindray is a leading medical company. As trade barriers are thrown up around the world, it has the potential to benefit should there be a shift in China towards buying domestically sourced products.